Screener
ARS Pharmaceuticals, Inc. SPRY Free cash flow
Free cash flow at other companies
Other financials
Where this comes from
Calculated from ARS Pharmaceuticals, Inc.’s reported figures.
The source filing: ARS Pharmaceuticals, Inc.’s 10-Q, filed August 13, 2026. Open the filing →
- Filed
- Aug 13, 2026, 4:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-349140
FAQ
- What is ARS Pharmaceuticals, Inc.'s free cash flow?
- ARS Pharmaceuticals, Inc. (SPRY) reported free cash flow of -$60.93M in Q2 2026.
- How has ARS Pharmaceuticals, Inc.'s free cash flow changed year-over-year?
- ARS Pharmaceuticals, Inc.'s free cash flow decreased by 53.7% year-over-year, from -$39.64M to -$60.93M.
- What is the long-term trend for ARS Pharmaceuticals, Inc.'s free cash flow?
- Over 3 years (2022 to 2025), ARS Pharmaceuticals, Inc.'s free cash flow has grown at a 62.0% compound annual growth rate (CAGR), from -$40.28M to -$171.21M.
- What does free cash flow mean?
- Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.
Ask your AI about ARS Pharmaceuticals, Inc.'s free cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude